Michael B Maris, MD

About

Michael Maris, MD, is a board-certified, fellowship-trained medical oncologist who focuses on the treatment of myeloid and lymphoid diseases. Dr. Maris has decades of experience treating these types of blood cancers through innovative therapies, especially blood and marrow transplantation. He believes in shared decision making, partnering with his patients by providing clear information about the disease and treatment options, empowering them to make the best decisions for their own care plans.

Dr. Maris earned his undergraduate degree at West Virginia University and went on to complete his medical degree at the University of Pennsylvania. He then completed an internal medicine residency at the Oregon Health Sciences University in Portland, OR followed by an oncology and blood and marrow transplantation fellowship at the Fred Hutchinson Cancer Research Center/University of Washington in Seattle, WA. Dr. Maris' fellowship research focus was expanding the role of allogeneic transplantation to older and infirm patients through the use of non-myeloablative allogeneic hematopoietic stem cell transplantation and he has published extensively in this area.

Dr. Maris' current research interests are in further optimizing allogeneic hematopoietic transplantation for patients of all types as well as the development of novel drug and drug regimens for the treatment of the patients with acute myeloid leukemia. Dr. Maris has extensive experience as an investigator in multiple clinical trials and Dr. Maris has expertise in the treatment of patients with acute myeloid leukemia.

In his free time, Dr. Maris enjoys spending time with his family as well as hiking, skiing, running, biking, and travel.

Care Philosophy:

I am dedicated to providing patients with the most up-to-date information about their disease and latest treatment options and then providing their chosen care with clinical excellence. It’s my goal that patients partner in their care plans, feeling empowered to make care decisions and having understanding of their disease and available treatments.